Status:

UNKNOWN

Validation of Questionnaire in Retinal Degeneration

Lead Sponsor:

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Collaborating Sponsors:

Street Lab

Conditions:

Retinal Degeneration

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

While inherited retinal diseases are well characterized anatomically and functionally, it is also essential to understand their impact on patients' quality of life, from their ability to perform the t...

Detailed Description

Interventional research of category 2 with minimal risks and constraints. This is a prospective, monocentric, longitudinal, non-randomized study to validate the translation of questionnaires to assess...

Eligibility Criteria

Inclusion

  • Male or female
  • Age: 18 to 80
  • Sufficient knowledge of the French language to ensure understanding of the tasks to be performed and the instructions received.
  • Signed consent after being informed by the investigator.
  • Affiliation with health insurance.
  • Affected by one of the following rare pathologies, with different levels of visual field, acuity and contrast sensitivity impairment:
  • Non-syndromic rod-cone dystrophy (retinopathy pigmentosa, RP): diagnosis confirmed by a specialist.
  • Non-syndromic rod-cone dystrophy: diagnosis confirmed by a specialist.
  • Non-syndromic Stargardt's disease: diagnosis confirmed by a specialist.
  • Non-syndromic congenital night blindness: diagnosis confirmed by a specialist.
  • Non-syndromic achromatopsia: diagnosis confirmed by a specialist.

Exclusion

  • Pregnancy
  • Inability to give informed consent.
  • Cataract surgery within 3 months of inclusion.
  • Hearing impairment that may interfere with comprehension during the interview.
  • Functional amblyopia.
  • Inability to comply with instructions to perform study tasks or study visits.
  • Drug treatment that may cause motor, visual or cognitive impairment (PSAs, neuroleptics, etc.) or that may interfere with study assessments.
  • Other uncontrolled ophthalmic conditions that may interfere with evaluation.
  • Participation in another clinical trial that may interfere with the present study.
  • Patient under guardianship, curatorship or legal protection

Key Trial Info

Start Date :

January 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

135 Patients enrolled

Trial Details

Trial ID

NCT06185517

Start Date

January 1 2024

End Date

January 1 2025

Last Update

December 29 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.